459423-07-5

Basic information

• Product Name: 7-(2-methoxyphenyl)benzo[d][1,3]dioxole-5-carbaldehyde
• Synonyms: 7-(2-methoxyphenyl)benzo[d][1,3]dioxole-5-carbaldehyde
• CAS NO: 459423-07-5
• Molecular Weight: 256.258
• Mol File: 459423-07-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 7-(2-methoxyphenyl)benzo[d][1,3]dioxole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(2-methoxyphenyl)benzo[d][1,3]dioxole-5-carbaldehyde(459423-07-5)
• EPA Substance Registry System: 7-(2-methoxyphenyl)benzo[d][1,3]dioxole-5-carbaldehyde(459423-07-5)

Safety Data

• Hazardous Substances Data: 459423-07-5(Hazardous Substances Data)

Upstream product

• 54246-05-8 3-iodo-4,5-dihydroxybenzaldehyde 
• 5438-36-8 5-iodovaniline 
• 1152538-80-1 7-iodobenzo[d][1,3]dioxole-5-carbaldehyde 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 19522-96-4 7-bromo-benzo[1,3]dioxole-5-carbaldehyde 
• 529-28-2 4-iodoanisol 

Relevant articles and documents

5-HT7receptor modulators: Amino groups attached to biphenyl scaffold determine functional activity

5-HT7receptor (5-HT7R) agonists and antagonists have been reported to be used for treatment of neuropathic pain and depression, respectively. In this study, as a novel scaffold for 5-HT7R modulators, we designed and prepared a series of biphenyl-3-yl-methanamine derivatives with various amino groups. Evaluation of functional activities as well as binding affinities of the title compounds identified partial agonists (EC50?=?0.55–3.2?μM) and full antagonists (IC50?=?5.57–23.1?μM) depending on the amino substituents. Molecular docking study suggested that the ligand-based switch in functional activity from agonist to antagonist results from the size of the amino groups and thereby different binding modes to 5-HT7R. In particular, interaction of the ligand with Arg367 of 5-HT7R is shown to differentiate agonists and antagonists. In the pharmacophore model study, two distinct pharmacophore models can tell whether a ligand is an agonist or an antagonist. Taken together, this study provides valuable information for designing novel compounds with selective agonistic or antagonistic properties against 5-HT7R.

Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein: (a) m is an integer 0 or 1; (b) R12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) - - - - - represents a bond present or absent; and (g) W, X, Y and Z are independently or together C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.